Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of
Hikal Limited
-(HIKAL)
XNSE:HIKAL, XBOM:HIKAL
Hikal Ltd Q4FY24; 6% fall in Profits
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of
Hikal Ltd Q3FY24; 38% fall in Profits
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of
Hikal Ltd Q2FY24; 48% fall in Profits
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of
Hikal ltd: Navigating the Pharmaceutical Landscape
Stock Data: TickerNSE: HIKALExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days-3.57 %YTD-24.35 %Last 12 Months-18.52%As on 14-09-2023 Company Description: Hikal Ltd is a dynamic
Hikal Ltd Q1FY24; 2% rise in Revenue
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of
Earnings Summary Of Hikal Limited For Q4 FY23
Hikal Limited is a leading global chemical company based in India. With over three decades of experience, the company specializes in the
Earnings Summary Of Hikal Limited For Q3 FY23
Hikal Limited (NSE: HIKAL) is a leading Indian life sciences company with a global presence. The company specializes in developing and manufacturing
Hikal Limited (HIKAL) Q3 FY23 Earnings Concall Transcript
Hikal Limited (NSE:HIKAL) Q3 FY23 Earnings Concall dated Feb. 02, 2023. Corporate Participants: Sameer Hiremath -- Managing Director Manoj Mehrotra -- President, Pharmaceuticals Vimal Kulshrestha -- President, Crop
Hikal Limited (HIKAL) Q2 FY23 Earnings Concall Transcript
Hikal Limited (NSE:HIKAL) Q2 FY23 Earnings Concall dated Aug. 11, 2022 Corporate Participants: Sameer Hiremath -- Managing Director Manoj Mehrotra -- President-Pharmaceuticals Vimal
Hikal Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/3z2q_SR1OS4 Key highlights from Hikal Limited (HIKAL) Q4 FY22 Earnings Concall Management Update: HIKAL said its new product launches in anti-diabetic have
Hikal Limited (HIKAL) Q4 FY22 Earnings Concall Transcript
Hikal Limited (NSE: HIKAL) Q4 FY22 Earnings Concall dated Jun. 03, 2022 Corporate Participants: Anish Swadi -- Senior President of Animal Health and Business
Hikal Limited Q3 FY22 Earnings Conference Call Insights
Key highlights from Hikal Limited (HIKAL) Q3 FY22 Earnings Concall Management Update: HIKAL stated that the company expects some short term impact